Biomea Fusion, Inc. (BMEA)
0.8689
+0.03
(+3.89%)
USD |
NASDAQ |
Oct 16, 16:00
0.8899
+0.02
(+2.42%)
After-Hours: 20:00
Biomea Fusion Research and Development Expense (Annual) : 61.98M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 61.98M |
| December 31, 2024 | 118.08M |
| December 31, 2023 | 102.55M |
| December 31, 2022 | 62.71M |
| Date | Value |
|---|---|
| December 31, 2021 | 28.00M |
| December 31, 2020 | 3.671M |
| December 31, 2019 | 1.092M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| REGENXBIO, Inc. | 212.68M |
| Compass Therapeutics, Inc. | 55.69M |
| ACADIA Pharmaceuticals, Inc. | 328.80M |
| Alnylam Pharmaceuticals, Inc. | 1.320B |
| Anika Therapeutics, Inc. | 25.77M |